Loading...
Market
El Paso reports decrease in mpox cases by end of 2024 compared to 2023?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
El Paso Department of Public Health annual reports on mpox cases
Story
WHO Approves Bavarian Nordic's Mpox Vaccine for Adolescents Amid Global Concern
Oct 14, 2024, 08:15 AM
The World Health Organization (WHO) has approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the disease. This approval, announced on October 14, is expected to speed up the distribution of the vaccine globally. The WHO's decision comes amidst rising global concern about mpox, which has seen an increase in cases this year. In Kenya, the Ministry of Health has recorded 13 cases and one death. Health experts in El Paso, Texas, have also noted a rise in mpox cases compared to last year, recommending vaccination for those most at risk. The MVA-BN vaccine has shown 58% effectiveness in preventing mpox in the short term, while tecovirimat appears safe but its effectiveness remains unconfirmed.
View original story
Similar markets
Los Angeles • 25%
New York City • 25%
Houston • 25%
Miami • 25%
Less than 5,000 • 25%
5,000 to 10,000 • 25%
10,001 to 20,000 • 25%
More than 20,000 • 25%
Less than 5 • 25%
5-10 • 25%
11-20 • 25%
More than 20 • 25%
Yes • 50%
No • 50%
Democratic Republic of Congo • 25%
Kenya • 25%
Nigeria • 25%
Burundi • 25%
0-2 • 25%
3-5 • 25%
6-10 • 25%
More than 10 • 25%
Less than 500 • 25%
500 to 1,000 • 25%
1,001 to 2,000 • 25%
More than 2,000 • 25%
Less than 25,000 • 25%
25,000 to 34,999 • 25%
35,000 to 44,999 • 25%
45,000 or more • 25%